Bis-styrylpyridine and bis-styrylbenzene derivatives as inhibitors for Aβ fibril formation

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 5, 2007, Pages 1466-1470

  Byeon, Seong Rim ^a,b   Lee, Ji Hoon ^a   Sohn, Ji Hoon ^c   Kim, Dong Chan ^a   Shin, Kye Jung ^a   Yoo, Kyung Ho ^a   Mook Jung, Inhee ^c   Lee, Won Koo ^b   Kim, Dong Jin ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Sogang University   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

A fibril formation inhibitor; Alzheimer disease; Amyloid ; Bis styrylbenzene; Bis styrylpyridine

Indexed keywords

ACRIDINE ORANGE; AMYLOID BETA PROTEIN; BENZENE DERIVATIVE; CURCUMIN; NOOTROPIC AGENT; PYRIDINE DERIVATIVE; THIOFLAVINE;

ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50;

AMYLOID BETA-PROTEIN; ANIMALS; BENZENE DERIVATIVES; CELL LINE; CELL SURVIVAL; DRUG DESIGN; INHIBITORY CONCENTRATION 50; MICE; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; STYRENES; THIAZOLES;

EID: 33846931387     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.10.090     Document Type: Article

References (20)

1. Cutler N.R., and Sramek J.J. Progr. Neuro-Psychopharmacol. Biol. Psychiatr. 25 (2001) 27
2. Meyer-luemen M. Nat. Neurosci. 6 (2003) 1
3. Nussbaum R.L., and Ellis C.E.N. Engl. J. Med. 348 (2003) 1356
4. Hardy J., and Selkoe D.J. Science 297 (2002) 353
5. Thorsett E.D., and Latimer L.H. Curr. Opin. Chem. Biol. 4 (2000) 377
6. Vickers J.C., Dickson T.C., Adlard P.A., Sounders H.L., King C.E., and McCormack G. Prog. Neurobiol. 60 (2000) 139
7. Hammarstrom P., Wiseman R.L., Powers E.T., and Kelly J.W. Science 299 (2003) 713
8. Dominquez D.I., and De Strooper B. Trends Pharmacol. Sci. 23 (2002) 324
9. Lashuel H.A., Petre B.M., Wall J., Simon M., Nowak R.J., Walz T., and Lansbury P.T. J. Mol. Biol. 322 (2002) 1089
10. Volles M.J., and Lansbury P.T. Biochemistry 42 (2003) 7871
11. Lee K.H., Shin B.H., Shin K.J., Kim D.J., and Yu J. Biochem. Biophys. Res. Commun. 328 (2005) 816
12. Revine III H. Arch. Biochem. Biophys. 404 (2002) 106 In vitro ThT assay: the final concentration of Aβ 42 (Bachem) was 25 μM. The excitation and emission wavelengths were 450 and 482 nm with 10 nm slit (LS-55 luminescence spectrometer: Perkin-Elmer)
13. MTT assay: MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was added into the HT-22 cell. Cell viability was estimated by measuring the absorbance of MTT formazan at 570 nm with a microplate reader. All compounds were tested as the HCl salt form. Compound II-3 was tested in the state of a free-form and a HCl-salt form as an example.
14. Lee C.W., Zhuang Z.P., Kung M.P., Plössl K., Skovronsky D., Gur T., Hou C., Trojanowski J.Q., Lee W.M.Y., and Kung H.F. J. Med. Chem. 44 (2001) 2270
15. Mathis C.A., Wang Y., and Klunk W.E. Curr. Pharm. Design 10 (2004) 1469
16. Ono M., Kung M.P., Hou C., and Kung H.F. Nucl. Med. Biol. 29 (2002) 633
17. Suemoto T., Okamura N., Shiomitsu T., Suzuki M., Shimadzu H., Akatsu H., Yamamota T., Kudo Y., and Sawada T. Neurosci. Res. 48 (2004) 65
18. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., Chen P., Kayed R., Glabe C.G., Frautschy S.A., and Cole G.M. J. Biol. Chem. 280 (2005) 5892
19. Chainani-Wu N. J. Altern. Complement Med. 9 (2003) 161
20. 2: C, 77.97; H, 7.05; N, 6.99. Found: C, 78.41; H, 7.18; N, 6.57.